This article was originally published on LivewireMarkets.com on April 16th, 2025

You know things are bad when 1kg of chocolate costs nearly the same price as our biggest bank. That’s right, the RRP of the Lindt Gold Bunny 1kg is $135, compared to $158.70 for Commonwealth Bank. I think it’s a fair comparison: Lindt is arguably, the elite of the supermarket chocolate brands, while Commbank is the elite of the banks.

Let’s break that down.

The Lindt 1kg Chocolate Bunny fights it out with CBA, courtesy of Canva’s Dream Lab

Consider our 1kg Lindy Gold Bunny. Imagine you can exercise some restraint and don’t wolf it down in one hit, you might get 20 days of pleasure out of it, 40 days if you follow Lindt’s 25g a day serving size (that’s barely a mouthful…). Then it’s gone… well not entirely, your waistline may still be digesting the 540g of sugar you ingested. But the point is, no more chocolate and money gone.

Then turn to Commonwealth Bank, which stands as a Strong Sell in Market Index’s broker consensus tool and many experts have described as being overvalued. Even factoring that, for your $158.70, you are accruing capital growth and dividends. Even if markets blow up, you could sell it in the 20 days you’ve taken to eat your Lindt Bunny and get most of your money back. That said, much like the challenge of digesting 540g of sugar, if markets gain and you make a return out of selling those shares, your little slice of indigestion might be a capital gains tax to hit come tax time.

Now, I like chocolate as much as the next person (more actually… the Livewire team are well aware of my addiction), but these prices are quite frankly appalling. And while I’ve referenced the Lindt bunny, let’s face it – the sharp increase in cocoa prices has really hit even the old basics like the Cadbury Crème Egg.

It’s time to make a stand – buy shares instead for Easter (and then, overindulge on discounted chocolate a few days later… I’m not so dramatic as to cut chocolate completely). Your portfolio will love you – your waistline might too (until post-Easter…).

Last year, I invited a crack team of experts to form the Aussie Equities Easter Bunny Advisory Committee (AEEBAC) and asked them to sort the chocolate from the carob.

That is, what companies might be the chocolate eggs – that is, popular but not necessarily great for your bottom line – compared to carob – aka less exciting but offering a solid long-term player in your portfolio… The healthy choice?

The AEEBAC is back for 2025, with the following good sports agreeing to support the cause:

• Bradley Clibborn, Portfolio Manager for Bennelong Funds Management
• Emanuel Datt, Principal for Datt Capital
• Justin Woerner, Portfolio Manager for Elston Asset Management
• Steve Johnson, Chief Investment Officer for Forager

The AEEBAC 2025 from LtoR: Bradley Clibborn, Emanuel Datt, Justin Woerner and Steve Johnson.

The chocolate eggs – short-term satisfaction but watch out for the future

Interestingly, all the nominations sit in the Financials sector – should you be worried? Read on…

1. The Banks – Bradley Clibborn and Steve Johnson

My reference to Commonwealth Bank (ASX: CBA) at the start of this article should have been a clue to Australian banks being included here. The Australian banks have been a significant driver of returns (and dividends) in portfolios over the past decades, but there are increasing concerns about their valuations and future prospects.

“A lack of effective reinvestment and increasing competition meant that earnings growth has been anaemic for much of the past decade,” says Clibborn, adding that mortgage brokers now originate 75% of all new mortgages and have been responsible for competition.

“The combination of high valuations while earnings growth prospects are at all-time lows is a very difficult position from which to generate solid returns. In addition, we expect the buying from superannuation funds to slow,” he adds.

Johnson agrees and narrows to Commonwealth Bank specifically.

“At today’s price, it’s a 3% dividend yield and 27x earnings for a business that won’t grow much. I find it hard to see it doing much better than government bonds over the long-term,” he says.

1 year share price performance for CBA. Source: Market Index, 15 April 2025

2. Zip Co (ASX: ZIP) – Emanuel Datt

The Buy-Now-Pay-Later (BNPL) sector has been interesting to watch, with consolidation and significant change across the pure-play companies in this space.

“Zip rose to fame during the BNPL boom alongside Afterpay, riding the wave of digital finance enthusiasm and millennial adoption. It was a darling of growth-focused retail investors,” says Datt.

The start of rate rises in 2022 hit many companies hard, but there has since been some recovery. While Market Index’s broker consensus tool positions Zip Co as a Strong Buy, Datt holds concerns.

“While topline revenues have grown, the company has consistently posted heavy operating losses and burned through cash. Profitability remains fleeting and tightening credit conditions have made its business model riskier,” Datt says, highlighting that bigger players like Apple, and even traditional banks, have entered the BNPL space and created competition.

“Zip is exciting in theme, widely recognised, and speculative in nature—but doesn’t pass our test for sustainable, high-quality compounders,” Datt says.

1 year share price performance for ZIP. Source: Market Index, 15 April 2025

3. Generation Development Group (ASX: GDG) – Justin Woerner

The diversified financial services business has generated strong revenue and ranks as a Strong Buy in Market Index’s broker consensus tool. But Woerner believes the medium term is not as promising.

“With growth coming from the managed accounts segment, we believe the overall quality of the businesses is diminishing. We believe management significantly overpaid for Evidentia at a time when competition within the managed accounts market is escalating.

Competition that is likely to increase the cost of customer acquisition and place downwards pressure on fees. We also query management’s ability to generate operating leverage within some aspects of the business, noting the consulting segment is highly people intensive,” Woerner says.

1 year share price performance for GDG. Source: Market Index, 15 April 2025

The carob eggs – long-term solid players for your portfolio

These names might not sound as exciting, but investing in them could provide a great long-term boost to your portfolio. Notably, all of these are trading far cheaper than the aforementioned chocolate bunny on a per share basis – and one (IDX) is even cheaper per share than the RRP of a crème egg.

1. James Hardie (ASX: JHX) – Bradley Clibborn

Purely looking at share prices, the market has taken a big bite out of James Hardie’s share price over the past few months. Clibborn explains the fibre cement manufacturer has generated some debate over its acquisition of Azek – it fell 14.5% the day of the announcement and a further 10% since due to concerns over the acquisition – but Trump’s tariffs have also come into play.

Clibborn thinks it is relatively well insulated from tariffs. He believes that the earnings growth outlook of the new combined entity is worth investing in.

“Our work confirms that Azek is a high-quality business with a long runway for growth. The growth drivers of AZEK are similar to JHX’s siding business in that we expect Azek to grow by converting homeowners to their superior composite and PVC decking products from traditional wood offerings.

We also believe that Azek will be able to broaden its sales by leveraging JHX’s strong customer network and superior contractor offering,” Clibborn says.

Clibborn also views current prices as an opportunity, highlighting that James Hardie is trading at the bottom of its historical PE range – and Azek has traditionally also traded at a premium to James Hardie.

“We expect that the combined group should be able to grow earnings by strong double digits percentage over the next three to five years,” Clibborn says.

Market Index’s broker consensus tool appears to agree, ranking James Hardie as a Buy.

1 year share price performance for JHX. Source: Market Index, 15 April 2025

2. Integral Diagnostics (ASX: IDX) – Emanuel Datt

The Australian diagnostic imaging company ranks as a Strong Buy on Market Index’s broker consensus tool, and Datt notes it benefits from its procurement scale, digital infrastructure and clinical systems.

“Around 85% of its revenue is Medicare-funded, making it highly defensive and largely insulated from economic cycles. Imaging volumes tend to grow steadily with population growth and irrespective of macro volatility,” says Datt.

He also sees a long runway to consolidate smaller imaging providers and integrate AI into workflows.

“While it’s not fast-growing, IDX consistently delivers mid-single digit revenue growth, solid cash conversion, and a reliable dividend yield,” Datt comments.

---

If you would like more information, please call 1300 ELSTON or contact us.